Showing 2661-2670 of 3153 results for "".
- Sasakawa Leprosy (Hansen's Disease) Launches New "Don't Forget Leprosy" Initiativehttps://practicaldermatology.com/news/sasakawa-leprosy-hansens-disease-new-initiative-dont-forget-leprosy/2460872/Sasakawa Leprosy (Hansen's Disease) Initiative is launching a campaign called "Don't Forget Leprosy" urging that activities against the disease are not sidelined amid the ongoing coronavirus pandemic. Beginning with a webinar on Aug. 4, 2021, the approximately 10-
- Sirnaomics Doses First Patient in Phase 2b Study of STP705 for Treatment of Squamous Cell Skin Cancerhttps://practicaldermatology.com/news/sirnaomics-doses-first-patient-in-phase-2b-study-of-stp705-for-treatment-of-squamous-cell-skin-cancer/2460857/Sirnaomics, Inc. dosed the first patient in a Phase 2b study of the company's drug candidate, STP705, for the trea
- Dove, Conservation International Announce Million Dollar Forest Restoration Project to Fight Climate Changehttps://practicaldermatology.com/news/dove-conservation-international-announce-million-dollar-forest-restoration-project-to-fight-climate-change/2460822/Dove is launching the Dove Forest Restoration Project, one of the biggest protection and restoration efforts from any beauty brand to-date. The project is designed to protect and restore forests, protect the habitats of endangered species, and improve the livelihoods of 16,000 peo
- Kintor Doses First Group of Acne Patients in Phase I/II Clinical Trial of Pyrilutamidehttps://practicaldermatology.com/news/kintor-doses-first-group-of-acne-patients-in-phase-iii-clinical-trial-of-pyrilutamide/2460752/Kintor Pharmaceutical Limited successfully dosed the first group of patients in the clinical trial of Pyrilutamide as a treatment for the acne vulgaris. The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evalu
- Dermata Doses First Patient in Phase 1b Trial of Topical DMT310 for Mild-to-Moderate Psoriasishttps://practicaldermatology.com/news/dermata-doses-first-patient-in-phase-1b-trial-of-topical-dmt310-for-mild-to-moderate-psoriasis/2460726/Dermata Therapeutics, Inc. dosed its first patient in a Phase 1b trial of DMT310 for the treatment of mild-to-moderate psoriasis. DMT310 is currently being investigated to treat multiple inflammatory skin diseases. It consists of a once-weekly topical treatment with both mech
- Dominion Aesthetic Technologies Closes $23.7 Million Series B Financing to Accelerate the Commercialization of EONhttps://practicaldermatology.com/news/dominion-aesthetic-technologies-closes-237-million-series-b-financing-to-accelerate-the-commercialization-of-eon/2460672/Dominion Aesthetic Technologies, developers of EON, closed Series B financing, raising a total of $23.7 million. The series B funding will accelerate the manufacturing and commercialization of EON, an FDA-cleared 1064 nm robotic laser device used for touchless, external non-invasi
- Cutera Gives Back: Company Donates Tattoo Removal Laser to Gang Rehabilitation and Re-entry Programhttps://practicaldermatology.com/news/cutera-gives-back-company-donates-tattoo-removal-laser-to-gang-rehabilitation-and-re-entry-program/2460597/Cutera, Inc. is donating an enlighten tatoo removal laser along with clinical training and service to Homeboy Industries, a gang rehabilitation and re-entry program in Los Angeles. Homeboy Industries provides parenting classes, anger management and tattoo removal to support former
- Kerecis Scores DoD Grant to Develop, Test New Fish-skin Wound Treatment for Soldiershttps://practicaldermatology.com/news/kerecis-scores-dod-grant-to-develop-test-new-fish-skin-wound-treatment-for-soldiers/2460561/The U.S. Department of Defense (DoD) awarded a grant of almost $600,000 to Kerecis to test the company’s fish-skin technology to better stabilize battlefield wounds and provide a bacterial barrier for them during evacuation. The grant money will be disbursed to Kerecis over
- Forte Biosciences, Inc. Announces First Patient Dosed in Study of FB-401 for the Treatment of Children and Adults With ADhttps://practicaldermatology.com/news/forte-biosciences-inc-announces-first-patient-dosed-in-study-of-fb-401-for-the-treatment-of-children-and-adults-with-ad/2460541/The first patient has been dosed in Forte Biosciences, Inc.’s clinical trial of FB-401 for the treatment of atopic dermatitis (AD). The multi-center, placebo controlled clinical trial of FB-401 is expected to enroll approximately 124 pediatric, adolescent and adult subjects aged 2
- Dr. Doris Day Joins Nufabrx’s Ad Boardhttps://practicaldermatology.com/news/dr-doris-day-joins-nufabrxs-ad-board/2460523/New York City dermatologist Doris Day, MD is the newest member of Nufabrx’s advisory board. Nufabrx is an advanced textiles company that has developed a proprietary biomaterial platform that embeds active ingredients into fabrics to